紫杉醇联合顺铂化疗对非小细胞肺癌患者外周血淋巴细胞表型的影响  

Observation of changes in peripheral lymphocyte subsets by flow cytometry in patients with non small cell lung cancer treated with paclitaxel and cisplatin

作　　者：陈新[1] 于化鹏[1] 杨振峰[1] 方翼 

机构地区：[1]第一军医大学珠江医院呼吸内科,广东广州510282 [2]解放军 458医院内四科,广东广州510600

出　　处：《癌症》2000年第12期1149-1151,共3页Chinese Journal of Cancer

摘　　要：目的：探讨紫杉醇联合顺铂化疗对非小细胞肺癌（ non small cell lung cancer,NSCLC）患者机体免疫功能的影响。方法： 45例经病理学或细胞学确诊的 NSCLC患者，采用紫杉醇、顺铂联合化疗方案，应用流式细胞仪检测 CD3、 CD4、 CD8、 CD16、 CD19、 CD25阳性细胞的百分率。结果： NSCLC患者经紫杉醇联合顺铂化疗后 CD4、 CD4/CD8、 CD16、 CD25较化疗前显著升高（ P0.05）；化疗后 CD4、 CD4/CD8、 CD16、 CD25、 CD8、 CD19、 CD3与正常对照组无显著差异（ P >0.05）；鳞癌、腺癌及大细胞癌 3组间化疗前、化疗后各项指标之间无显著性差异（ P >0.05）。结论：紫杉醇联合顺铂化疗可改善机体的免疫功能。Objective: The current study was designed to investigate the changes in peripheral lymphocyte subsets by flow cytometry in patients with NSCLC treated with paclitaxel and cisplatin. Methods: From 45 patients of NSCLC (non small cell lung cancer) received chemotherapy of paclitaxel and cisplatin, 2 ml venous blood was obtained before and at the 20th day after chemotherapy. By using monoclonal antibodies, the blood samples were evaluated with the flow cytometry for T lymphocyte subsets, NK cell, CD19 cell and CD25 cell. Results: The expressive rates of CD4, CD16, CD25 and the ratio of CD4/CD8 in peripheral blood were higher in post treatment patients than in pre treatment samples (P0.05). There was no difference between post treatment and normal control group in the expressive rates of CD4,CD16,CD25,CD8,CD19,CD3 and the ratio of CD4/CD8. The data of pre treatment or post treatment were not different among three groups of adenocarcinoma， squamous cell carcinoma and large cell carcinoma. Conclusion:Chemotherapy combining paclitaxel with cisplatin for NSCLC can activate patients' immune function.

关 键 词：紫杉醇 顺铂 非小细胞肺癌 淋巴细胞表型 

分 类 号：R734.2[医药卫生—肿瘤]